Andrew Evens Joins Rutgers Cancer Institute of New Jersey and RWJBarnabas Health

Andrew M. Evens, DO, MSc, FACP

Andrew M. Evens, DO, MSc, FACP

Lymphoma expert Andrew M. Evens, DO, MSc, FACP, has joined Rutgers Cancer Institute of New Jersey as associate director. He is also serving as medical director of the oncology service line at RWJBarnabas Health. Evens will focus on integrated cancer care delivery in his roles across both institutions.

As associate director at Rutgers Cancer Institute, he will oversee and aid in the integration of all multidisciplinary clinical programs across the Institute, with attention toward survivorship, palliative care, and navigational support. He will also serve as director of the Lymphoma Program in the Division of Blood Disorders, where he will lead a translational lymphoma laboratory that utilizes systems biology analyses and investigates novel targeted therapeutic agents for lymphoma.

As medical director at RWJBarnabas Health, Evens will encourage the development of an integrated cancer care delivery platform that spans the health system. He will also serve as a professor of medicine at Rutgers Robert Wood Johnson Medical School.

“Dr Evens’ leadership skills and clinical expertise complement the mission of Rutgers Cancer Institute—the state’s only NCI-designated Comprehensive Cancer Center—in delivering the highest quality of cancer care. His role in enhancing integrated cancer care in concert with RWJBarnabas Health, will promote the growth of clinical research and clinical services that will enable us to further address the oncology needs of the state of New Jersey and beyond,” said Steven K. Libutti, MD, FACS, director of the Rutgers Cancer Institute, in a statement.

Previously, Evens served as the chief of the Division of Hematology/Oncology and director of the Tufts Cancer Center at Tufts Medical Center. At Tufts, Evens also served as a professor of medicine and was named the Chan Soon-Shiong Endowed Scholar in Precision Medicine. He is affiliated with several organizations both nationally and internationally, including the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and the Scientific Advisory Board for the Lymphoma Research Foundation.

“I look forward to helping enhance the clinical mission of both Rutgers Cancer Institute and RWJBarnabas Health. By further emphasizing the strengths of our collective advanced clinical offerings and exploring innovative opportunities for improved and additional cancer care services, we will have a valuable impact on oncology outcomes for patients across the region,” Evens said in a statement.

A renowned physician scientist, he has been the principle investigator for more than 75 clinical trials focused on the treatment of lymphoma, and maintained a R01-funded translational lymphoma laboratory examining lymphoma biology, signal transduction pathways, free radical-mediated biology, and the development of novel targeted agents for the treatment of lymphoma.

He has authored or co-authored more than 150 original articles, is currently an associate editor for theBritish Journal of Hematology,and sits on the editorial board of theJournal of Clinical Oncology.

Evens received his medical degree from Chicago College of Osteopathic Medical. He later completed an internal medicine residency at Lutheran General Hospital in Park Ridge, Illinois, where he served as chief medical resident. His fellowship in hematology/oncology was completed at the Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center.